deltatrials
Completed PHASE2 NCT00002466

Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer

Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Kidney Cancer Sarcoma
Interventions conventional surgery cyclophosphamide doxorubicin hydrochloride etoposide ifosfamide radiation therapy vincristine sulfate
Updated 5 times since 2017 Last updated: Jun 19, 2013 Started: May 31, 1990 Primary completion: May 31, 2005 Completion: May 31, 2005

This PHASE2 trial investigates Kidney Cancer and Sarcoma and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 5 recorded versions since 1990 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

May 1990

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States